- Home
- CASS vs MNPR Comparison
CASS vs MNPR Comparison
Compare CASS & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASS
- MNPR
- Stock Information
- Founded
- CASS 1906
- MNPR 2014
- Country
- CASS United States
- MNPR United States
- Employees
- CASS N/A
- MNPR N/A
- Industry
- CASS Business Services
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- CASS Consumer Discretionary
- MNPR Health Care
- Exchange
- CASS Nasdaq
- MNPR Nasdaq
- Market Cap
- CASS 503.5M
- MNPR 531.6M
- IPO Year
- CASS 1996
- MNPR 2019
- Fundamental
- Price
- CASS $41.19
- MNPR $78.00
- Analyst Decision
- CASS Buy
- MNPR Strong Buy
- Analyst Count
- CASS 2
- MNPR 13
- Target Price
- CASS $45.50
- MNPR $97.83
- AVG Volume (30 Days)
- CASS 106.4K
- MNPR 146.8K
- Earning Date
- CASS 10-23-2025
- MNPR 11-13-2025
- Dividend Yield
- CASS 3.10%
- MNPR N/A
- EPS Growth
- CASS 37.29
- MNPR N/A
- EPS
- CASS 2.31
- MNPR N/A
- Revenue
- CASS $222,318,000.00
- MNPR N/A
- Revenue This Year
- CASS N/A
- MNPR N/A
- Revenue Next Year
- CASS $7.33
- MNPR N/A
- P/E Ratio
- CASS $20.36
- MNPR N/A
- Revenue Growth
- CASS 7.50
- MNPR N/A
- 52 Week Low
- CASS $36.08
- MNPR $16.26
- 52 Week High
- CASS $47.00
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- CASS 60.87
- MNPR 44.18
- Support Level
- CASS $39.06
- MNPR $77.50
- Resistance Level
- CASS $42.07
- MNPR $89.03
- Average True Range (ATR)
- CASS 1.02
- MNPR 6.39
- MACD
- CASS 0.31
- MNPR -0.84
- Stochastic Oscillator
- CASS 77.50
- MNPR 15.78
About CASS Cass Information Systems Inc
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. It operates in two segments: Information Services and Banking Services. The firm generates maximum revenue from the Information Services segment, which provides transportation, energy, telecommunication, and environmental invoice processing and payment services to large corporations.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.